Back to mobile site

JPMorgan Continues to See 2024 AS an 'execution year' for BioNTech (BNTX)

March 20, 2024 2:37 PM EDT Send to a Friend
JPMorgan analyst Jessica Fye reiterated a Neutral rating and {REMOVEPT} price target on BioNTech (NASDAQ: BNTX)The analyst comments "We continue ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login